Fullständiga villkor Bilaga A
VILLKOR FÖR TECKNINGSOPTIONER SERIE 2023:A I ONDOSIS AB TERMS AND CONDITIONS FOR WARRANTS SERIES 2023:A IN ONDOSIS AB
-
-
Kallelse till årsstämma i OnDosis AB
Aktieägarna i OnDosis AB (publ), org.nr 559113-1825, kallas härmed till årsstämma tisdagen den 27 juni 2023 kl. 10.00 i Bolagets lokaler i GoCo House, 5 tr, Gemenskapens gata 9 i Mölndal.
Insläpp och registrering sker vid entrén kl. 09.30.
-
United States Patent and Trademark Office issues OnDosis first patent April 11th
OnDosis, a MedTech company aiming to revolutionize the way patients take their medicines, announced the issuance by the USPTO of its 1st patent relating to the company’s device technology, a first in category Dosage Manager.
-
Emplicure and OnDosis announce partnership to develop better pain treatments
Emplicure AB och OnDosis AB utvärderar gemensamma utvecklingsmål för oral dosering av aktiva substanser baserade på bolagens respektive unika teknologier inom formulering och dosering.
-
TIEFENBACHER GROUP and OnDosis launch the innovative healthcare brand OYSTA®
TIEFENBACHER GROUP and OnDosis are thrilled to announce the launch of OYSTA®. The new healthcare brand represents the cooperation initiated in September 2020, including the co-development portfolio of innovative products in five indications. OYSTA® aims to revolutionize the way how patients take their medicines by combining pharmaceuticals with e-health technology to enable intuitive, precise, and
-
OnDosis och Stardots ingår ett strategiskt samarbete för att kombinera banbrytande teknologier och möjliggöra bättre terapier för Parkinsons sjukdom
OnDosis, ett svenskt medicinteknikbolag som utvecklar en unik device-plattform för flexibel och individanpassad dosering av läkemedel, och Stardots, ett svenskt digitalt hälsobolag som utvecklar produkter inom neurologi, meddelar idag att bolagen ingått ett strategiskt samarbete. Avsikten är att kombinera bolagens banbrytande teknologier för att möjliggöra utveckling av unika produkter för beh -
OnDosis completes a private placement of SEK 75 million supported by AstraZeneca and Aeternum Capital
OnDosis, a Swedish Life science company developing a new drug/device technology platform, announced today that the Company has completed a private placement of SEK 75 million. Investors in the private placement include OnDosis founders AstraZeneca and Martin Olovsson and major shareholders Aeternum Capital, DIG Investment and Rydgruppen
-
Kallelse till årsstämma i OnDosis AB / Notice of annual general meeting 2022
Aktieägarna i OnDosis AB, org.nr 559113-1825 (”OnDosis” eller ”Bolaget”), kallas härmed till årsstämma tisdagen den 28 juni 2022 kl. 10.00 i Bolagets lokaler på AstraZeneca Bio VentureHub, Pepparedsleden 1 i Mölndal. Insläpp och registrering sker vid AstraZeneca KC entrén kl. 09:45.
The shareholders of OnDosis AB, reg. no. 556582-6558, (“OnDosis” or the “Company”) are hereby given notice of Ann -
OnDosis completes a private placement of SEK 92 million led by Aeternum Capital
OnDosis, a Swedish Life science company developing a new device technology platform, announced today that the Company has completed a pre-IPO private placement of SEK 92 million. Investors in the private placement include Aeternum Capital, DIG Investment and Albonja.
The private placement follows the successful expansion of the strategic collaboration between OnDosis and Tiefenbacher -
New agreement expands collaboration between OnDosis and Tiefenbacher Group, paving way for a revolution in how patients with rare disease take their medicines
Swedish Life science company OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new innovative development projects targeting ADHD, rare diseases and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine.
Tiefenbacher Group is a pioneering healthcar -
New agreement expands collaboration between OnDosis and Tiefenbacher Group, opening a new chapter in precision medicine for rare disease and transplantation medicine
Swedish Life science company OnDosis and German B2B pharmaceutical company Tiefenbacher Group initiate four new innovative development projects targeting ADHD, rare diseases and transplantation medicine. The idea is to improve the health and everyday lives of millions of patients by giving them access to finely tuned and individualized medicine
-
OnDosis completes a private placement of SEK 92 million led by Aeternum Capital
OnDosis, a Swedish Life science company developing a new device technology platform, announced today that the Company has completed a pre-IPO private placement of SEK 92 million. Investors in the private placement include Aeternum Capital, DIG Investment and Albonja.
Visa mer
Loading...